vs
Side-by-side financial comparison of ImmunityBio, Inc. (IBRX) and TPG Mortgage Investment Trust, Inc. (MITT). Click either name above to swap in a different company.
ImmunityBio, Inc. is the larger business by last-quarter revenue ($38.3M vs $20.4M, roughly 1.9× TPG Mortgage Investment Trust, Inc.). TPG Mortgage Investment Trust, Inc. runs the higher net margin — 65.0% vs -161.8%, a 226.8% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs 17.7%).
ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.
TPG Mortgage Investment Trust, Inc. is a real estate investment trust managed by global alternative asset firm TPG. It primarily invests in residential and commercial mortgage-backed securities, performing and non-performing mortgage loans, and other credit-linked real estate assets, with its core market being the United States. It generates returns via net interest income from holdings and strategic asset disposition gains.
IBRX vs MITT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $38.3M | $20.4M |
| Net Profit | $-61.9M | $13.3M |
| Gross Margin | 99.0% | — |
| Operating Margin | -169.0% | 67.1% |
| Net Margin | -161.8% | 65.0% |
| Revenue YoY | 407.0% | 17.7% |
| Net Profit YoY | -4.7% | -7.0% |
| EPS (diluted) | $-0.06 | $0.27 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $38.3M | $20.4M | ||
| Q3 25 | $32.1M | $19.5M | ||
| Q2 25 | $26.4M | $17.8M | ||
| Q1 25 | $16.5M | $18.8M | ||
| Q4 24 | $7.6M | $17.4M | ||
| Q3 24 | $6.1M | $14.9M | ||
| Q2 24 | — | $16.4M | ||
| Q1 24 | — | $17.2M |
| Q4 25 | $-61.9M | $13.3M | ||
| Q3 25 | $-67.3M | $20.0M | ||
| Q2 25 | $-92.6M | $3.9M | ||
| Q1 25 | $-129.6M | $11.5M | ||
| Q4 24 | $-59.2M | $14.3M | ||
| Q3 24 | $-85.7M | $16.6M | ||
| Q2 24 | — | $3.9M | ||
| Q1 24 | — | $20.9M |
| Q4 25 | 99.0% | — | ||
| Q3 25 | 99.4% | — | ||
| Q2 25 | 99.5% | — | ||
| Q1 25 | 99.6% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -169.0% | 67.1% | ||
| Q3 25 | -173.5% | — | ||
| Q2 25 | -269.8% | 20.9% | ||
| Q1 25 | -390.1% | 54.6% | ||
| Q4 24 | -919.0% | 76.7% | ||
| Q3 24 | -1314.3% | — | ||
| Q2 24 | — | 18.4% | ||
| Q1 24 | — | — |
| Q4 25 | -161.8% | 65.0% | ||
| Q3 25 | -209.8% | 102.5% | ||
| Q2 25 | -350.3% | 22.2% | ||
| Q1 25 | -784.9% | 60.9% | ||
| Q4 24 | -783.4% | 82.2% | ||
| Q3 24 | -1404.0% | 111.3% | ||
| Q2 24 | — | 24.0% | ||
| Q1 24 | — | 121.6% |
| Q4 25 | $-0.06 | $0.27 | ||
| Q3 25 | $-0.07 | $0.47 | ||
| Q2 25 | $-0.10 | $-0.05 | ||
| Q1 25 | $-0.15 | $0.21 | ||
| Q4 24 | $-0.08 | $0.30 | ||
| Q3 24 | $-0.14 | $0.40 | ||
| Q2 24 | — | $-0.02 | ||
| Q1 24 | — | $0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $242.8M | $57.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-500.5M | $560.7M |
| Total Assets | $501.9M | $8.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $242.8M | $57.8M | ||
| Q3 25 | $257.8M | $59.0M | ||
| Q2 25 | $153.7M | $88.7M | ||
| Q1 25 | $61.6M | $115.5M | ||
| Q4 24 | $149.8M | $118.7M | ||
| Q3 24 | $130.4M | $102.5M | ||
| Q2 24 | — | $120.9M | ||
| Q1 24 | — | $100.3M |
| Q4 25 | $-500.5M | $560.7M | ||
| Q3 25 | $-524.3M | $559.8M | ||
| Q2 25 | $-570.7M | $536.4M | ||
| Q1 25 | $-591.4M | $543.9M | ||
| Q4 24 | $-489.1M | $543.4M | ||
| Q3 24 | $-745.1M | $540.1M | ||
| Q2 24 | — | $533.5M | ||
| Q1 24 | — | $539.6M |
| Q4 25 | $501.9M | $8.7B | ||
| Q3 25 | $519.0M | $9.0B | ||
| Q2 25 | $402.1M | $7.5B | ||
| Q1 25 | $303.8M | $7.3B | ||
| Q4 24 | $382.9M | $6.9B | ||
| Q3 24 | $364.6M | $7.0B | ||
| Q2 24 | — | $7.1B | ||
| Q1 24 | — | $6.4B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-70.4M | $59.6M |
| Free Cash FlowOCF − Capex | $-71.3M | — |
| FCF MarginFCF / Revenue | -186.2% | — |
| Capex IntensityCapex / Revenue | 2.4% | — |
| Cash ConversionOCF / Net Profit | — | 4.48× |
| TTM Free Cash FlowTrailing 4 quarters | $-308.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-70.4M | $59.6M | ||
| Q3 25 | $-68.9M | $17.4M | ||
| Q2 25 | $-79.7M | $11.5M | ||
| Q1 25 | $-85.9M | $12.0M | ||
| Q4 24 | $-85.1M | $55.8M | ||
| Q3 24 | $-98.8M | $14.5M | ||
| Q2 24 | — | $13.7M | ||
| Q1 24 | — | $12.0M |
| Q4 25 | $-71.3M | — | ||
| Q3 25 | $-69.6M | — | ||
| Q2 25 | $-80.8M | — | ||
| Q1 25 | $-87.0M | — | ||
| Q4 24 | $-87.3M | — | ||
| Q3 24 | $-101.6M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -186.2% | — | ||
| Q3 25 | -217.2% | — | ||
| Q2 25 | -305.9% | — | ||
| Q1 25 | -526.9% | — | ||
| Q4 24 | -1155.4% | — | ||
| Q3 24 | -1663.2% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 2.4% | — | ||
| Q3 25 | 2.3% | — | ||
| Q2 25 | 4.1% | — | ||
| Q1 25 | 6.8% | — | ||
| Q4 24 | 28.0% | — | ||
| Q3 24 | 45.7% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 4.48× | ||
| Q3 25 | — | 0.87× | ||
| Q2 25 | — | 2.92× | ||
| Q1 25 | — | 1.05× | ||
| Q4 24 | — | 3.91× | ||
| Q3 24 | — | 0.87× | ||
| Q2 24 | — | 3.50× | ||
| Q1 24 | — | 0.57× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
